⏳ Fetching live dividend data...
Home › Calculator › FRTX Dividend Calculator 2026
Fresh Tracks Therapeutics, Inc. · NASDAQ
Price: $0.94 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in FRTX → $1089853929079093.88M in 10 years · $90,779,715,915,584,780,000.00/month
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime.
Ready to invest? Open FRTX position with:
Real after-tax yield depends on where you live and how you hold FRTX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 213.90% | 211.10% | $21,390 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 181.81% | 179.01% | $18,182 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 171.12% | 168.32% | $17,112 / yr |
| 🇬🇧 UK ISA | 0% | 213.90% | 211.10% | $21,390 / yr |
| 🇬🇧 UK Taxable | 8.75% | 195.18% | 192.38% | $19,518 / yr |
| 🇨🇦 TFSA | 0% | 213.90% | 211.10% | $21,390 / yr |
| 🇨🇦 CA Taxable | 25% | 160.43% | 157.63% | $16,043 / yr |
| 🇦🇺 Super (pension) | 15% | 181.81% | 179.01% | $18,182 / yr |
| 🇦🇺 AU Taxable | 30% | 149.73% | 146.93% | $14,973 / yr |
| 🇩🇪 DE Taxable | 26.375% | 157.48% | 154.68% | $15,748 / yr |
| 🇫🇷 FR Taxable | 30% | 149.73% | 146.93% | $14,973 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
FRTX pays quarterly — 4 times per year. Next ex-div: TBD.
How FRTX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for FRTX sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Buy | 2024-06-10 | 86,185 | $0.94 | $81.0K | ||
| Buy | 2024-06-07 | 319,315 | $0.94 | $300.2K | ||
| Buy | 2024-05-31 | 516 | $0.89 | $459.00 | ||
| Buy | 2024-05-30 | 9,838 | $0.92 | $9.1K | ||
| Buy | 2024-05-29 | 80 | $0.87 | $70.00 | ||
| Buy | 2024-05-23 | 15,627 | $0.91 | $14.2K | ||
| Buy | 2024-05-22 | 383 | $0.89 | $341.00 | ||
| Buy | 2024-05-21 | 6,879 | $0.91 | $6.3K | ||
| Buy | 2024-05-20 | 797 | $0.91 | $725.00 | ||
| Buy | 2024-05-16 | 73,768 | $0.92 | $67.9K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the FRTX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →